At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
KRN23drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
In Brief
A Phase 2 clinical trial evaluating KRN23 for X-linked Hypophosphatemia. Completed, enrolled 23 participants across 6 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsX-linked Hypophosphatemia
CountriesCanada, United States
CollaboratorsKyowa Hakko Kirin Pharma, Inc.
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedApr 2012
Primary CompletionSep 2013
Study CompletionJun 2014
TodayJul 2026
First PostedApr 5, 2012
Enrollment StartFeb 1, 2012
Primary CompletionSep 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.2 years ago
Interventions
KRN23drug
Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.